Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder

Leonardo F. Fontenelle; Mauro V. Mendlowicz; Euripedes C. Miguel; Marcio Versiani

doi:10.1080/15622970510029740

Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder

Leonardo F. Fontenelle, Mauro V. Mendlowicz, Euripedes C. Miguel, Marcio Versiani

Research output: Contribution to journal › Article › Research › peer-review

6 Citations (Scopus)

Abstract

While serotonin reuptake inhibitors (SRIs) are the first-line treatment of obsessive-compulsive disorder (OCD), as many as 40-60% of patients fail to respond to adequate trials with these drugs. In this study, we describe the case of a patient with an SRI-resistant OCD who was successfully treated with a combination of citalopram (a selective SRI) and reboxetine (a selective noradrenaline reuptake inhibitor (SNRI)). This report suggests that future studies accessing the efficacy of the SRI-SNRI combination in treatment resistant OCD are needed.

Original language	English
Pages (from-to)	57-59
Number of pages	3
Journal	The World Journal of Biological Psychiatry
Volume	6
Issue number	1
DOIs	https://doi.org/10.1080/15622970510029740
Publication status	Published - 7 Jun 2005
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Citalopram
Obsessive-compulsive disorder
Reboxetine

Access to Document

10.1080/15622970510029740

Cite this

@article{37a6ecf2ea0b493c8b2235374ebc6c42,

title = "Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder",

abstract = "While serotonin reuptake inhibitors (SRIs) are the first-line treatment of obsessive-compulsive disorder (OCD), as many as 40-60\% of patients fail to respond to adequate trials with these drugs. In this study, we describe the case of a patient with an SRI-resistant OCD who was successfully treated with a combination of citalopram (a selective SRI) and reboxetine (a selective noradrenaline reuptake inhibitor (SNRI)). This report suggests that future studies accessing the efficacy of the SRI-SNRI combination in treatment resistant OCD are needed.",

keywords = "Citalopram, Obsessive-compulsive disorder, Reboxetine",

author = "Fontenelle, \{Leonardo F.\} and Mendlowicz, \{Mauro V.\} and Miguel, \{Euripedes C.\} and Marcio Versiani",

year = "2005",

month = jun,

day = "7",

doi = "10.1080/15622970510029740",

language = "English",

volume = "6",

pages = "57--59",

journal = "The World Journal of Biological Psychiatry",

issn = "1562-2975",

publisher = "Taylor \& Francis",

number = "1",

}

TY - JOUR

T1 - Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder

AU - Fontenelle, Leonardo F.

AU - Mendlowicz, Mauro V.

AU - Miguel, Euripedes C.

AU - Versiani, Marcio

PY - 2005/6/7

Y1 - 2005/6/7

N2 - While serotonin reuptake inhibitors (SRIs) are the first-line treatment of obsessive-compulsive disorder (OCD), as many as 40-60% of patients fail to respond to adequate trials with these drugs. In this study, we describe the case of a patient with an SRI-resistant OCD who was successfully treated with a combination of citalopram (a selective SRI) and reboxetine (a selective noradrenaline reuptake inhibitor (SNRI)). This report suggests that future studies accessing the efficacy of the SRI-SNRI combination in treatment resistant OCD are needed.

AB - While serotonin reuptake inhibitors (SRIs) are the first-line treatment of obsessive-compulsive disorder (OCD), as many as 40-60% of patients fail to respond to adequate trials with these drugs. In this study, we describe the case of a patient with an SRI-resistant OCD who was successfully treated with a combination of citalopram (a selective SRI) and reboxetine (a selective noradrenaline reuptake inhibitor (SNRI)). This report suggests that future studies accessing the efficacy of the SRI-SNRI combination in treatment resistant OCD are needed.

KW - Citalopram

KW - Obsessive-compulsive disorder

KW - Reboxetine

UR - https://www.scopus.com/pages/publications/19444382365

U2 - 10.1080/15622970510029740

DO - 10.1080/15622970510029740

M3 - Article

C2 - 16097406

AN - SCOPUS:19444382365

SN - 1562-2975

VL - 6

SP - 57

EP - 59

JO - The World Journal of Biological Psychiatry

JF - The World Journal of Biological Psychiatry

IS - 1

ER -

Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Cite this